TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20396719
Drug: Artrofoon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artrofoon treatment for 2 years
Study: 14970135
Drug: Alkalinized lidocaine-filled
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine-filled ETT cuff with water-soluble gel lubrication (Group G)
Study: 14970135
Drug: Alkalinized lidocaine-filled
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine-filled cuffs (Group G and W)
Study: 9143860
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1)
Study: 9143860
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2)
Study: 8182635
Drug: Supervised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group physical therapy (3 hours weekly)
Study: 8182635
Drug: Unsupervised daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised daily individualized exercises at home (9 months)
Study: 24121121
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (CMT)
Study: 8808130
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluvoxamine
Study: 8944409
Drug: Fluvoxamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine treatment
Study: 11422727
Drug: Fluvoxamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine and paroxetine treatment
Study: 11422727
Drug: Acute discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute discontinuation
Study: 8129449
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral flucloxacillin 250 mg/day (group P, n = 18)
Study: 25156424
Drug: Dried California
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried California Mission figs (120 g/d)
Study: 21442809
Drug: Routine medicine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medicine, physical therapy, occupational therapy, and other rehabilitation trainings
Study: 19845037
Drug: Metformin (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (arm A; n = 59)
Study: 19845037
Drug: Metformin (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (arm A)
Study: 11742271
Drug: LEV 0.31
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 0.31 mg
Study: 11742271
Drug: LEV 0.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 0.63 mg
Study: 11742271
Drug: RAC 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC 1.25 mg
Study: 11742271
Drug: RAC 2.5
Normalized name: Dolorac 2.5 MG/ML Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC 2.5 mg
Study: 8359579
Drug: Lysine acetylsalicilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicilate (450 mg i.v.)
Study: 21512258
Drug: Subcutaneous fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous fondaparinux
Study: 30284557
Drug: Oral edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral edoxaban
Study: 26137702
Drug: Xiaoaiping injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoaiping injection (60 mL, i.v., qd)
Study: 16357551
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy supplemented with partial weight‐bearing gait training twice weekly
Study: 15124980
Drug: Cinnarizine 20
Normalized name: cinnarizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevert, ARL)
Study: 15124980
Drug: Dimenhydrinate 50
Normalized name: dimenhydrinate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 50 mg
Study: 2908307
Drug: All medications
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All medications
Study: 8642030
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution after closure of the wound (Group 2)
Study: 8642030
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution before the incision (Group 1)
Study: 8642030
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mL of plain saline solution for both injections, Group 3)
Study: 20614235
Drug: EEG Biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG Biofeedback (Neurofeedback‐NFB) treatment, 20 sessions over 4 weeks
Study: 20614235
Drug: Escitalopram treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment, 10 mg per day for 8 weeks
Study: 20614235
Drug: EEG Biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG Biofeedback (Neurofeedback‐NFB) treatment
Study: 3304367
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg three times a day
Study: 6412224
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and atenolol
Study: 19788364
Drug: Systemic estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic estrogen therapy
Study: 27982198
Drug: LT4/LT3 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT4/LT3 therapy (75/15 μg/day)
Study: 27982198
Drug: LT4 treatment
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 treatment (125 or 150 μg/day)
Study: 26585192
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g oral azithromycin
Study: 18184245
Drug: Morphine 25
Normalized name: apomorphine 25 mg sublingual film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 25 microg.kg(‐1) in 2% lidocaine hydrochloride with 1 : 1 00 000 epinephrine
Study: 11092066
Drug: 21 mg/24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/24-hour patch
Study: 11092066
Drug: 15 mg/16-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/16-hour patch
Study: 1592965
Drug: Brushing frequency
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brushing frequency twice per day
Study: 23837551
Drug: cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive behavioral therapy (15 sessions)
Study: 20228986
Drug: G1 (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1 (control group with orientation regarding oral hygiene)
Study: 18544018
Drug: Antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drugs (ARVs)
Study: 16185306
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) die(‐1) for 30 days
Study: 15321815
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Fe (Fe group)
Study: 15321815
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Zn (Zn group)
Study: 12663287
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Fe + 10 mg Zn (Fe+Zn group)
Study: 11573726
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial infusion with 5‐fluorouracil/doxorubicin
Study: 11573726
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial infusion
Study: 30915991
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg PF‐06372865
Study: 30915991
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg PF‐06372865
Study: 27025186
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg once-daily alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C)
Study: 27025186
Drug: Placebo alongside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo alongside chemotherapy then placebo only maintenance (arm A)
Study: 27025186
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg once-daily alongside chemotherapy then placebo only maintenance (arm B)
Study: 20194414
Drug: Social recovery‐focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social recovery‐focused cognitive‐behavioral therapy (SRCBT)
Study: 12631309
Drug: Community-based Directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based Directly Observed Treatment (CBDOT)
Study: 12631309
Drug: Institutional-based Directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institutional-based Directly Observed Treatment (IBDOT)
Study: 10839907
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine and 0.5 microg/ml sufentanil
Study: 10839907
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine and 0.5 microg/ml sufentanil
Study: 12053678
Drug: Intracoronary radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiotherapy with a prescribed dose of 17 Gy delivered via a Re‐188 filled balloon catheter.
Study: 7641968
Drug: Intravenous sulprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sulprostone after cervical priming with dinoprostone
Study: 7641968
Drug: Intramuscular sulprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular sulprostone only
Study: 7641968
Drug: Intravenous sulprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sulprostone only
Study: 21481708
Drug: Cytomegalovirus glycoprotein-B
Normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant
Study: 15312255
Drug: sCT 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT 1.0 mg (daily)
Study: 15312255
Drug: sCT (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT (various doses)
Study: 11340522
Drug: Poorly absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poorly absorbable antifungal agents
Study: 11340522
Drug: Absorbable antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable antifungal agents
Study: 11340522
Drug: No antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifungal prophylaxis
Study: 1378156
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg once daily
Study: 17288679
Drug: Losartan-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-based therapy
Study: 20583956
Drug: Moxifloxacin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin monotherapy
Study: 18074762
Drug: Test fixed
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test fixed dose combination of nitazoxanide 500 mg and ofloxacin 200 mg
Study: 18074762
Drug: Reference fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference fixed dose combination of nitazoxanide 500 mg and ofloxacin 200 mg
Study: 15821687
Drug: 0.4% stannous
Normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% stannous fluoride gel (SFG) for 4 minutes
Study: 9972758
Drug: Epidural steroids
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroids administered with fluoroscopic guidance
Study: 9972758
Drug: Epidural steroids
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroids administered without fluoroscopic guidance
Study: 2332096
Drug: Pulsatile glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulsatile glucagon delivery (377 ng/min for 2 min followed by 11 min with no infusion)
Study: 6996158
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penicillins, probenecid, a sulphonamide and ornidazole (once-only administration)
Study: 6996158
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penicillins, probenecid, a sulphonamide and metronidazole
Study: 30788788
Drug: Single-Strand Assembly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Strand Assembly (SSA) methods for combinatorial pathway engineering; details on dosage and duration not available.
Study: 30788788
Drug: Combinatorial multigene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinatorial multigene pathway assembly scheme based on SSA and Golden Gate Assembly; details on dosage and duration not available.
Study: 23652196
Drug: Pressure patching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure patching with ofloxacin ointment (patch group, PG)
Study: 23652196
Drug: Ofloxacin ointment
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin ointment alone (ointment group, OG)
Study: 18201563
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin/day
Study: 8915127
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms subcutaneously every 8 hours for a maximum of six doses)
Study: 8915127
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment with intravenous fluid replacement and antibiotic treatment)
Study: 6882062
Drug: Praziquantel, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel, single oral dose of 30 mg kg‐1
Study: 31084635
Drug: Dynamic Interpersonal
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic Interpersonal Therapy (DIT), 16 sessions over approximately 5 months
Study: 31084635
Drug: Low-Intensity Treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Treatment (LIT), control intervention
Study: 21463169
Drug: Dynamic Interpersonal
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic Interpersonal Therapy (DIT)
Study: 28179351
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus S-1 chemotherapy
Study: 19491035
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo administration of diclofenac sodium pellets
Study: 16307008
Drug: Dapoxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 60 mg + Tadalafil 20 mg
Study: 16307008
Drug: Dapoxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 60 mg + Sildenafil 100 mg
Study: 10903223
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of albuterol
Study: 10903223
Drug: As-needed use
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed use of albuterol
Study: 9068463
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg for 4 weeks followed by either lansoprazole 30 mg or 60 mg for another 4 weeks
Study: 9068463
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. for 8 weeks
Study: 8438610
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization with cholera toxin B-subunit
Study: 3101242
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (3 ml intramuscular iron dextran)
Study: 30049223
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg of inhaled vaporized cannabis (18.2% Δ9‐tetrahydrocannabinol, <0.1% cannabidiol)
Study: 30049223
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg of placebo control cannabis (CTRL; 0.33% Δ9‐tetrahydrocannabinol, <0.99% cannabidiol)
Study: 23795576
Drug: VAL/HCT fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL/HCT fixed-dose combination (FDC) tablet
Study: 23795576
Drug: VAL +
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VAL + HCT (concomitant administration)
Study: 21091293
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g chicory native inulin
Study: 18364345
Drug: Internet-administered measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered measures
Study: 18364345
Drug: Telephone-administered measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered measures
Study: 16263174
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of latanoprost and timolol once daily in the evening
Study: 16263174
Drug: Unfixed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfixed combination of latanoprost once daily in the evening and timolol in the morning and evening
Study: 10576171
Drug: Phase 1
Normalized name: Coxiella burnetii phase 1 IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 treatment
Study: 10576171
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phase 1 treatment)
Study: 6452796
Drug: Zimelidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (300 mg)
Study: 26894169
Drug: Aprotinin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1 ml of 10,000 Kallikrein Inactivator Units sub‐mucosally injected)
Study: 26894169
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (1 ml injected as control)
Study: 24245554
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 0.03 mg/drospirenone (group 1)
Study: 15774256
Drug: OM-89 (immunotherapeutic);
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-89 (immunotherapeutic); 1 capsule per day for 90 days, followed by 3 months without treatment, then 10 days in Months 7, 8, and 9.
Study: 15774256
Drug: Placebo; 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; 1 capsule per day for 90 days, followed by 3 months without treatment, then 10 days in Months 7, 8, and 9.
Study: 10099066
Drug: Claritin‐D 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claritin‐D 24 Hour (loratadine 10 mg and pseudoephedrine sulfate 240 mg)
Study: 10099066
Drug: Claritin‐D 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claritin‐D 12 Hour (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Study: 341283
Drug: Iron-dextran (Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-dextran (Total Dose Infusion)
Study: 26194125
Drug: Benachio Q
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benachio Q solution®
Study: 23040887
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg)
Study: 12687836
Drug: Bepridil, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil, 200 mg/day (n = 14)
Study: 12687836
Drug: Class Ic
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class Ic antiarrhythmic drugs (Flecainide, 100 to 200 mg/day (n = 15) or Pilsicainide, 75 to 150 mg/day (n = 23))
Study: 12687836
Drug: Class Ic
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class Ic antiarrhythmic drugs
Study: 8388332
Drug: Moderate-dose fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose fentanyl
Study: 8388332
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupuncture and TES with moderate-dose fentanyl
Study: 3812308
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean 371 mg)
Study: 3812308
Drug: Diltiazem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (mean 307 mg)
Study: 2774228
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg (group B)
Study: 2774228
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) (group B)
Study: 25222800
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia (CBTI‐BP; n = 17)
Study: 19709502
Drug: 1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/d of eicosapentaenoic acid (EPA) for 8 weeks
Study: 10571599
Drug: SB-207266-A (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-207266-A (20 mg)
Study: 8768852
Drug: Propranolol (10(‐4)
Normalized name: propranolol hydrochloride 4 MG/ML
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (10(‐4) mol/L)
Study: 8768852
Drug: Phentolamine (10(‐4)
Normalized name: phentolamine 10 MG/ML
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentolamine (10(‐4) mol/L)
Study: 24244335
Drug: Durable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable polymer drug-eluting stents (DES)